a reduction in the risk of mace that was greater than the general nb patient population tested in some embodiments the subject e g patient or patient population being treated by the methods disclosed herein is overweight or obese and at increased risk of an adverse cardiovascular event in some embodiments the mace is cardiovascular death nonfatal myocardial infarction nonfatal stroke in some embodiments the overweight or obese subject at increased risk of adverse cv event or mace has one or more characteristics or suffers from one or more of a history of cardiovascular disease cvd a current confirmed diagnosis or at high likelihood of cvd type 1 diabetes type 2 diabetes dyslipidemia for example elevated triglycerides elevated ldl or low hdl hypertension past or current smoker a family history of cvd a genetic predisposition of cvd unstable angina cardiac arrhythmia atrial fibrillation congestive heart failure and stroke in a preferred embodiment the subject is overweight or obese and at increased risk of a major adverse cardiovascular event and has type 2 diabetes mellitus t2dm for less than 6 years in another preferred embodiment the subject is overweight or obese and at increased risk of a major adverse cardiovascular event and is a current tobacco smoker in some embodiments the current smoker does not have t2dm in some embodiments the overweight or obese subjects that are at increased risk of adverse cv event or mace include subjects having one or more of the following conditions a cardiovascular disease cvd confirmed diagnosis or at an increased risk of cvd optionally with at least one of the following a history of documented myocardial infarction gt 3 months prior to screening or identification a history of coronary revascularization e g coronary artery bypass graft surgery.